Last €24.38 EUR
Change Today +0.62 / 2.59%
Volume 0.0
ACU On Other Exchanges
Symbol
Exchange
NASDAQ GS
Stuttgart
As of 11:56 AM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).

acadia pharmaceuticals inc (ACU) Snapshot

Open
€23.79
Previous Close
€23.76
Day High
€24.54
Day Low
€23.57
52 Week High
11/28/14 - €24.54
52 Week Low
04/15/14 - €12.49
Market Cap
2.4B
Average Volume 10 Days
22.8
EPS TTM
--
Shares Outstanding
99.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACADIA PHARMACEUTICALS INC (ACU)

acadia pharmaceuticals inc (ACU) Related Businessweek News

No Related Businessweek News Found

acadia pharmaceuticals inc (ACU) Details

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by Pimavanserin that is in the Phase III development as a first-in-class treatment for Parkinson’s disease psychosis, and in Phase II development for Alzheimer’s disease psychosis; and has completed Phase II trial as a co-therapy for schizophrenia. It also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced preclinical programs directed at Parkinson’s disease and other neurological disorders. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

48 Employees
Last Reported Date: 02/27/14
Founded in 1993

acadia pharmaceuticals inc (ACU) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $935.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $605.0K
Vice President, General Counsel, Corporate Co...
Total Annual Compensation: $445.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $178.1K
Compensation as of Fiscal Year 2013.

acadia pharmaceuticals inc (ACU) Key Developments

ACADIA Pharmaceuticals Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 09:20 AM

ACADIA Pharmaceuticals Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 09:20 AM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.

ACADIA Pharmaceuticals Inc. Announces Consolidated Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Updates Timing of NUPLAZID(TM) NDA Submission

ACADIA Pharmaceuticals Inc. announced consolidated unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported collaborative revenues of $15,000 compared with $240,000 for the same period a year ago. Loss from operations was $24,994,000 compared with $10,811,000 for the same period a year ago. Net loss was $24,786,000 or $0.25 per basic and diluted share compared with $10,695,000 or $0.12 per basic and diluted share for the same period a year ago. For the nine months, the company reported collaborative revenues of $72,000 compared with $1,108,000 for the same period a year ago. Loss from operations was $64,676,000 compared with $26,133,000 for the same period a year ago. Net loss was $64,109,000 or $0.66 per basic and diluted share compared with $25,899,000 or $0.31 per basic and diluted share for the same period a year ago. The company plans to submit its NUPLAZID NDA for Parkinson's disease psychosis in the first quarter of 2015. The company had previously planned to submit the NDA near the end of 2014. The decision to move back the planned submission is based on additional time required to complete preparations needed to support the U.S. Food and Drug Administration's (FDA) review of NUPLAZID. The change in submission timing is not a result of any change to NUPLAZID's clinical or safety profile, nor is it a result of any interaction with or request for information from the FDA. Additionally, ACADIA reported that it has successfully completed its drug-drug interaction program and its registration stability program.

ACADIA Pharmaceuticals Inc. to Report Q3, 2014 Results on Nov 10, 2014

ACADIA Pharmaceuticals Inc. announced that they will report Q3, 2014 results at 5:00 PM, US Eastern Standard Time on Nov 10, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACU:GR €24.38 EUR +0.62

ACU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACU.
View Industry Companies
 

Industry Analysis

ACU

Industry Average

Valuation ACU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27,338.9x
Price/Book 9.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 24,314.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACADIA PHARMACEUTICALS INC, please visit www.acadia-pharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.